Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Malvatricin
- Development stage
- Unknown
- Lead developer
- Laboratório Daudt
- Modality
- Peptides, Small Molecules
- Administration
- Topical, Buccal
01
Overview
Malvatricin is a topical antiseptic and antimicrobial combination product developed and marketed by Laboratório Daudt Oliveira Ltda, a Brazilian pharmaceutical company. The formulation contains two primary active ingredients: **hydroxyquinoline sulfate** and **tyrothricin**. Hydroxyquinoline sulfate acts as a broad-spectrum antiseptic, while tyrothricin is a mixture of cyclic and linear polypeptides (primarily gramicidins and tyrocidines) that exerts bactericidal activity by disrupting bacterial cell membranes, particularly against Gram-positive organisms. Malvatricin is indicated for the treatment of oropharyngeal infections, pharyngitis, and related conditions such as gingivitis and stomatitis. It acts locally within the oral cavity and oropharynx with minimal systemic absorption. The product is available in multiple dosage forms, including ready-to-use solutions, sprays, lozenges, and dental gels, and is registered with the Brazilian health regulatory authority, ANVISA.
- Brand names
- Malvatricin
- Other names
- Malvatricin PPUMalvatricin PastilhasMalvatricin SprayMalvatricin SoluçãoMalvatricin Gel Dental
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on Malvatricin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Malvatricin.